DAFTAR PUSTAKA

1. WHO.int. (17 Mei 2017). Cardiovascular Diseases (CVDs). Diakses pada tanggal 12 Februari 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
2. PERKI. Pedoman Tata Laksana Sindrom Koroner Akut 2018. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Published online 2018:7
3. Kementrian Kesehatan Republik Indonesia. Laporan Provinsi Sulawesi Selatan Riset Kesehatan Dasar (RISKESDAS) 2018. Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan. 2019.
4. Hamm CW, et al. ESC Guidelines for The Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation : The Task Force for The Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2011 Dec;32(23):2999- 3054
5. Fava C, et al. The Role of Red Blood Distribution Width (RDW) in Cardiovascular Risk Assessment: Useful or Hype?. Ann Trans Med. 2019;7(20):58
6. Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinical Proc. 2009.
7. Libby P, Simon DI. Inflammation and Thrombosis: The Clot Thickens. Circulation Journal. 2001;103:1718-1720

8. Falk E. Pathogenesis of Atherosclerosis. Journal of the American College of Cardiology. 2006.

9. Tuzcu EM, et al. High Prevalence of Coronary Atherosclerosis in Asymptomatic Teeneger and Young Adults. 2001

10. Apple FS, Pearce LA, Chung A, Ler R, et al. Multiple Biomarker Use for Detection of Adverse Events in Patients Presenting with Symptoms Suggestive of Acute Coronary Syndrome. Clin Chem, 2007; 53(5): 874–81

11. Davies MJ. The Pathophysiology of Acute Coronary Syndromes. Heart Journal. 2000 Mar;83(3):361-6.

12. Overbaugh KJ. Acute Coronary Syndrome. Am J Nurs. 2009 May;109(5):42-52.

13. Gutstein DE, Fuster V. Pathophysiology and Clinical Significance of Atherosclerotic Plaque Rupture. Cardiovasc Res. 1999 Feb;41(2):323-33

14. Libby P, Theroux P. Pathophysiology of Coronary Artery Disease. Circulation. 2005 Jun 28;111(25):3481-8

15. Fischer A, Gutstein DE, et al. Predicting Plaque Rupture: Enhancing Diagnosis and Clinical Decision-Making in Coronary Artery Disease. Vasc Med. 2000;5(3):163-72

16. Crea F, Liuzzo G. Pathogenesis of Acute Coronary Syndromes. J Am Coll Cardiology. 2013 Jan 8;61(1):1-11.

17. Fuster V, Badimon L, et al. The Pathogenesis of Coronary Artery Disease and The Acute Coronary Syndromes. New Englan Journal Medicine. 1992;

326:242- 250

18. Libby P, Ridker PM, Hansson GK. Progress and Challenges in Translating the Biology of Atherosclerosis. Nature Journal. 2011 May 19;473(7347):317-25

19. Nolan JP, Soar J, et al. European Resuscitation Council Guidelines for Resuscitation 2010. Resuscitation Journal. 2010 Oct;81(10):1219-76

20. Morrow DA, et al. B-Type Natriuretic Peptide and The Effect of Ranolazine in Patients with Non ST Segment Elevation Acute Coronary Syndromes: Observation From the MERLIN-TIMI 35 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST Elevation Acute Coronary Thrombolysis in Myocardial Infarction. Journal Am Coll Cardiology. 2010 Mar 23;55(12):1189-1196

21. deFilippi CR, Seliger SL. Biomarkers for Prognostication After Acute Coronary Syndromes: New Times and Statistics. Journal Am Coll Cardiology. 2009 Jul 21;54(4):365-7

22. Herbig BA, Diamond SL. Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation. J Thromb Haemost. 2015; 13(9):1699–1708. [PubMed: 26178390]

23. Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007; 120(Suppl 1):S5–S9. [PubMed: 17493665]

24. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007; 100(12):1673–1685. [PubMed: 17585075]

25. Rand JH, Glanville RW, Wu XX, et al. The significance of subendothelial von Willebrand factor. Thromb Haemost. 1997; 78(1):445–450. [PubMed: 9198194]

26. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell. 1996; 84(2):289–297. [PubMed: 8565074]

27. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature. 1999; 401(6755):808–811. [PubMed: 10548108]

28. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007; 117(4):953–960. [PubMed: 17380206]

29. van Gestel MA, Reitsma S, Slaaf DW, et al. Both ADP and thrombin regulate arteriolar thrombus stabilization and embolization, but are not involved in initial hemostasis as induced by micropuncture. Microcirculation. 2007; 14(3):193–205. [PubMed: 17454672]

30. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADPinduced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998; 273(4):2024–2029. [PubMed: 9442039]

31. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic

drugs. Expert review of cardiovascular therapy. 2007; 5(1):45–55. [PubMed: 17187456]

32. Brass, LF.; Newman, DK.; Wannemacher, KM.; Zhu, L.; Stalker, TJ. Signal transduction during platelet plug formation. In: Michelson, AD., editor. Platelets. 3rd. Boston, MA: Academic Press; 2013. p. 367-398

33. Mangin P, Yap CL, Nonne C, et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood. 2006; 107(11):4346– 4353. [PubMed: 16391010]

34. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995; 57:827–872.

35. Kansas GS. Selectins and their ligands: Current concepts and controversies. Blood 1996;88:3259–3287.

36. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell 1991;65:859–873

37. Takahashi M, Masuyama J, Ikeda U, Kitagawa S, Kasahara T, Saito M, Kano S, Shimada K. Effects of endogenous endothelial interleukin-8 on neutrophil migration across an endothelial monolayer. Cardiovasc Res 1995;29:670–675.

38. Luu NT, Rainger GE, Nash GB. Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils. J Immunol 2000;164:5961–5969.

39. Ahmed SR, McGettrick HM, Yates CM, Buckley CD, Ratcliffe MJ, Nash

GB, Rainger GE. Prostaglandin D2 regulates CD4+ memory T cell trafficking across blood vascular endothelium and primes these cells for clearance across lymphatic endothelium. J Immunol 2011; 187:1432–1439.

40. Muller WA. The role of pecam-1 (cd31) in leukocyte emigration: Studies in vitro and in vivo. J Leukoc Biol 1995;57:523–528.

41. Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009;105:223–230.

42. Lalor P, Nash GB. Adhesion of flowing leucocytes to immobilized platelets. Br J Haematol 1995;89:725–732.

43. Stone PC, Nash GB. Conditions under which immobilized platelets activate as well as capture flowing neutrophils. Br J Haematol 1999; 105:514–522.

44. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of mac1 with fibrinogen bound to alphaiibbeta3 and stimulated by plateletactivating factor. J Clin Invest 1997;100:2085–2093.

45. Rainger GE, Buckley C, Simmons DL, Nash GB. Cross-talk between cell adhesion molecules regulates the migration velocity of neutrophils. Curr Biol 1997;7:316– 325.

46. Rainger GE, Buckley CD, Simmons DL, Nash GB. Neutrophils sense flow-generated stress and direct their migration through alphavbeta3-integrin. Am J Physiol 1999;276: H858–H864.

47. Kuckleburg CJ, Yates CM, Kalia N, Zhao Y, Nash GB, Watson SP, Rainger GE. Endothelial cell-borne platelet bridges selectively recruit monocytes in

human and mouse models of vascular inflammation. Cardiovasc Res 2011;91:134–141.

48. Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol 2008;83: 1069–1078.

49. Suzuki J, Hamada E, Shodai T, Kamoshida G, Kudo S, Itoh S, Koike J, Nagata K, Irimura T, Tsuji T. Cytokine secretion from human monocytes potentiated by p- selectin-mediated cell adhesion. Int Arch Allergy Immunol 2013;160:152–160

50. Japp AG, Chelliah R, Tattersall L, Lang NN, Meng X, Weisel K, Katz A, Burt D, Fox KA, Feuerstein GZ, et al. Effect of psi-697, a novel p-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc 2013;2:e006007

51. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin mac-1 (cd11b/ cd18). J Exp Med 2000;192:193–204.

52. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115:451–459.

53. Tekelioglu Y, Uzun H, Gucer H. Circulating platelet-leukocyte aggregates in patients with inflammatory bowel disease. J Chin Med Assoc 2013;76:182–185.

54. Wrigley BJ, Shantsila E, Tapp LD, Lip GY. Increased formation of

monocyte- platelet aggregates in ischemic heart failure. Circ Heart Fail 2013;6:127–135.

55. Goncalves R, Zhang X, Cohen H, Debrabant A, Mosser DM. Platelet activation attracts a subpopulation of effector monocytes to sites of leishmania major infection. J Exp Med 2011;208:1253–1265.

56. Parimon T, Li Z, Bolz DD, McIndoo ER, Bayer CR, Stevens DL, Bryant AE. Staphylococcus aureus alpha-hemolysin promotes platelet-neutrophil aggregate formation. J Infect Dis 2013;208: 761–770.

57. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger III AL, Goldberg RJ, Michelson AD. Circulating monocyte- platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38:1002–1006.

58. Gkaliagkousi E, Corrigall V, Becker S, de Winter P, Shah A, Zamboulis C, Ritter J, Ferro A. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 2009;30:3048–3054.

59. Lippi G, Montagnana M, Salvagno GL, Cicorella N, Degan M, Minuz P, Lechi C, Guidi GC. Risk stratification of patients with acute myocardial infarction by quantification of circulating monocyte-platelet aggregates. Int J Cardiol 2007;115:101–102.

60. Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol 2013;200:373–383.

61. Varon D, Hayon Y, Dashevsky O, Shai E. Involvement of platelet derived

microparticles in tumor metastasis and tissue regeneration. Thromb Res 2012;130:S98–S99.

62. Cameron HA, Phillips R, Ibbotson RM, Carson PH. Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983; 287: 449–51.

63. Kilic¸li-Camur N, Demirtunc¸ R, Konuralp C, Eskiser A, Bas¸aran Y. Could mean platelet volume be a predictive marker for acute myocardial infarction? Med Sci Monit 2005; 11: CR387–92.

64. Martin JF, Plumb J, Kilbey RS, Kishk YT. Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed) 1983; 287: 456–9.

65. Endler G, Klimesch A, Sunder-Plassmann H et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399–404.

66. Damodar S, Ganesh KV, Murthy S. Mean platelet volume does not predict risk of myocardial infarction or coronary artery disease in Indian patients. Platelets 2008; 19: 80–1.

67. Kristensen SD, Bath PM, Martin JF. Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina. Cardiovasc Res 1990; 24: 19–23.

68. Kishk YT, Trowbridge EA, Martin JF. Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. Clin Sci (Lond) 1985; 68: 419–25.

69. Yilmaz MB, Saricam E, Biyikoglu SF et al. Mean platelet volume and

exercise stress test. J Thromb Thrombolysis 2004; 17: 115–20.

70. Muscari A, De Pascalis S, Cenni A et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 2008; 99: 1079–84.

71. Pizzulli L, Yang A, Martin JF, Lu¨deritz B. Changes in platelet size and count in unstable angina compared to stable angina or noncardiac chest pain. Eur Heart J 1998; 19: 80–4.

72. Cay S, Biyikoglu F, Cihan G, Korkmaz S. Mean platelet volume in the patients with cardiac syndrome X. J Thromb Thrombolysis 2005; 20: 175–8.

73. Jaumdally RJ, Varma C, Blann AD, MacFadyen RJ, Lip GY. Platelet activation in coronary artery disease: intracardiac vs peripheral venous levels and the effects of angioplasty. Chest 2007; 132: 1532–9

74. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409–11.

75. Huczek Z, Kochman J, Filipiak KJ et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284–90.

76. Smyth DW, Martin JF, Michalis L, Bucknall CA, Jewitt DE. Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 1993; 23: 361–7.

77. Yang A, Pizzulli L, Lu¨deritz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 2006; 117: 371–7.

78. O'Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995; 26: 995–9.

79. Butterworth RJ, Bath PM. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 1998; 9: 359–64.

80. Muscari A, Puddu GM, Cenni A et al. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thromb Res 2009; 123: 587–91.

81. Bath P, Algert C, Chapman N, Neal B, PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622–6.

82. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004; 35: 1688–91.

83. D'Erasmo E, Aliberti G, Celi FS, Romagnoli E, Vecci E, Mazzuoli GF. Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med 1990; 227: 11–4.

84. Dundar O, Yoruk P, Tutuncu L et al. Longitudinal study of platelet size changes in gestation and predictive power of elevated MPV in development

ofpre-eclampsia. Prenat Diagn 2008; 28: 1052–6.

85. Sullivan MH, Clark NA, de Swiet M, Nelson-Piercy C, Elder MG. Titration of antiplatelet treatment in pregnant women at risk of preeclampsia. Thromb Haemost 1998; 79: 743–6.

86. Colkesen Y, Acil T, Abayli B et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis 2008; 19: 411–4.

87. Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of ''healthy control subjects'' and ''disease control subjects'' in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957–64.

88. Bath PMW, Missouris CG, Buckenham T, MacGregor GA. Increased platelet volume and platelet mass in patients with atherosclerotic renal artery stenosis. Clin Sci 1994; 87: 2

89. Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. Acta Haematol 1999; 101: 140–4.

90. Guthikonda S, Alviar CL, Vaduganathan M et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743–9.

91. Sharpe PC, Trinick T. Mean platelet volume in diabetes mellitus. Q J Med 1993; 86: 739–42.

92. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat 2009; 23: 89–94.

93. Papanas N, Symeonidis G, Maltezos E et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475–8

94. Tschoepe D, Roesen P, Esser J et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991; 17: 433–8.

95. Davı` G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769–74.

96. Iwase E, Tawata M, Aida K et al. A cross-sectional evaluation of spontaneous platelet aggregation in relation to complications in patients with type II diabetes mellitus. Metabolism 1998; 47: 699–705

97. Poirier P, Eckel RH. Obesity and cardiovascular disease. Curr Atheroscler Rep 2002; 4: 448–53.

98. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005; 59: 981–2.

99. Coban E, Yilmaz A, Sari R. The effect of weight loss on the mean platelet volume in obese patients. Platelets 2007; 18: 212–6.

100. Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol, 2007; 49: 1841–1850.

101. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights from the Framingham Study. JAMA, 1992; 267: 1253–1256

102. Sabatine MS, Morrow DA, Cannon CP et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol, 2002; 40: 1761–1768.

103. Dehghani MR, Rezaei Y, Taghipour-Sani L. Superiority of total white blood cell count over other leukocyte differentials for predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome. Biomarkers, 2014; 19: 378–384.

104. Huang G, Zhong XN, Zhong B et al. Significance of white blood cell count and its subtypes in patients with acute coronary syndrome. Eur J Clin Invest, 2009; 39: 348–358.

105. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7: 157–61.

106. Dastjerdi MS, Emami T, Najafian A, Amini M. Mean platelet volume measurement, EDTA or citrate? Hematology 2006; 11: 317– 9.

107. Altaf A, Shah H, Salahuddin M. Gender based differences in clinical and Angiographic characteristics and outcomes of Acute Coronary Syndrome (ACS) in Asian population. Pak J Med Sci. 2019;35(5):1349-54.

108. Dugani SB, Hydoub YM, Ayala AP, Reka R, Nayfeh T, Ding JF, McCafferty SN, Alzuabi M, Farwati M, Murad MH, Alsheikh-Ali AA, Mora S. Risk Factors for Premature Myocardial Infarction: A Systematic Review and Meta-analysis of 77 Studies. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun 23;5(4):783-794. doi: 10.1016/j.mayocpiqo.2021.03.009. PMID: 34401655; PMCID: PMC8358212.

109. Banks E, Joshy G, Korda RJ, Stavreski B, Soga K, Egger S, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Medicine. 2019;17(1):128.

110. Himbert D, Klutman M, Steg G, White K, Gulba DC. Cigarette smoking and acute coronary syndromes: a multinational observational study. International journal of cardiology. 2005;100(1):109-17.

111. Yilmaz M, Tenekecioglu E, Arslan B, et al. White Blood Cell Subtypes and Neutrophil–Lymphocyte Ratio in Prediction of Coronary Thrombus Formation in Non-ST-Segment Elevated Acute Coronary Syndrome. Clinical and Applied Thrombosis/Hemostasis.2015;21(5):446-452. doi:10.1177/1076029613507337

112. Byrne CE, Fitzgerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Medical Genetics. 2004;5(1):13.

113. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: Implications for risk assessment. Journal of the

American College of Cardiology. 2004;44(10):1945-56.

114. Çiçek G, Açıkgöz SK, Yayla Ç, Kundi H, İleri M. White blood cell count to mean platelet volume ratio: A novel and promising prognostic marker for ST-segment elevation myocardial infarction. Cardiology journal. 2016;23(3):225-35.

115. Sivri S, Sokmen E, Celik M, Ozbek SC, Yildirim A, Boduroglu Y. Usefulness of white blood cell count to mean platelet volume ratio in the prediction of SYNTAX score in patients with non-ST elevation myocardial infarction. Pak J Med Sci. 2019;35(3):824-9.

116. Reddy SK, Shetty R, Marupuru S, Yedavalli N, Shetty K. Significance of Platelet Volume Indices in STEMI Patients: A Case-Control Study. Journal of clinical and diagnostic research : JCDR. 2017;11(4):Lc05-lc7.

117. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, et al. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. 2017;10(9):e004981.

118. Dehghani MR, Rezaei Y, Fakour S, Arjmand N. White Blood Cell Count to Mean Platelet Volume Ratio Is a Prognostic Factor in Patients with Non-ST Elevation Acute Coronary Syndrome with or without Metabolic Syndrome. Korean circulation journal. 2016;46(2):229-38.

119. Emre AR, Yasar KA, Atakan Y, Orhan C, Murathan K. Relationship between White Blood Count to Mean Platelet Volume Ratio and Clinical Outcomes and Severity of Coronary Artery Disease in Patients Undergoing Primary Percutaneous Coronary Intervention. Cardiovascular Therapeutics.

2020;2020:9625181.

120. Pellizzon GG, Dixon SR, Stone GW, Cox DA, Mattos L, Boura JA, et al. Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial). The American journal of cardiology. 2003;91(6):729-31.

121. Chang HY, Hsu LW, Lee CH, Lin CC, Huang CW, Chen PW, et al. Impact of Platelet Volume on the Clinical Outcomes of Patients with Acute Coronary Syndrome. Acta Cardiologica Sinica. 2019;35(6):563-70.

LAMPIRAN

1. Rekomendasi Persetujuan Etik Penelitian

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 468/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 26 Agustus 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22060284	No Sponsor Protokol	
Peneliti Utama	**dr. Deni Syamsuddin**	Sponsor	
Judul Peneliti	Rasio Leukosit dan Volume Rerata Trombosit (WMR) Sebagai Prediktor Major Adverse Cardiac Events (MACE) Jangka Menengah pada Penderita Sindrom Koroner Akut		
No Versi Protokol	**2**	Tanggal Versi	**26 Agustus 2022**
No Versi PSP	**2**	Tanggal Versi	**26 Agustus 2022**
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **26 Agustus 2022** sampai **26 Agustus 2023**	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET, DAN TEKNOLOGI UNIVERSITAS HASANUDDIN KOMISI ETIK PENELITIAN KESEHATAN FAKULTAS KEDOKTERAN

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan